MAPK3 and non-small cell lung carcinoma: Notably, 1 μM canertinib also inhibits ErbB1-3 receptor phosphorylation and decreases Akt-, ERK1/2-, and Stat3 activity in both cell lines.186–189 Canertinib was enrolled in clinical trials in December 2002, and completed studies investigating its efficacy in combination with paclitaxel/carboplatin for the first-line treatment of NSCLC (NCT00174356), as well as in patients with metastatic (stage IV) breast cancer (NCT00051051) and as a single agent for the treatment of advanced NSCLC (NCT00050830) between 2002 and 2007.